Checked daily
Drug shortages right now
219 drugs (1,504 products) are in shortage or being discontinued in the US, from FDA's shortage list, checked every day. Find yours, see which makers are affected and what's still available.
Checked
Amino Acid Injection Gastroenterology
- Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)
- Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)
- Plenamine, Injection, 0.15 (NDC 0264-4500-00)
- Plenamine, Injection, 0.15 (NDC 0264-4500-05)
- Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)
- Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)
- Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)
- PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18...
- Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100...Estimated recovery: December 2026
- Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100...
- Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100...
And 1 more presentations.
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet Psychiatry
- Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)
- Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)
- Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)
- Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)Estimated recovery: November 2026
- Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)
- Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)
- Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)
- Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg...Estimated recovery: 1Q 2027
- Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg...Estimated recovery: TBD
- Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg...
- Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg...
- Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg...
- Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg...Estimated availability: April 2027
- Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg...Estimated recovery: TBD
- Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg...
And 58 more presentations.
Atropine Sulfate Injection Anesthesia, Neurology, Pediatric
- Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)Discontinuation of the manufacture of the drug
- Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)Discontinuation of the manufacture of the drug
- Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)
- Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)On allocation
- Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)Estimated recovery: TBD
- Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)Estimated availability: December 2026
- Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)Next release November 2026. Check wholesalers for inventory.
- Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)
- Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)
- Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)
- Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)
- Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)
- Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)
- Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)Estimated availability: December 2026
- Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)
And 2 more presentations.
Azacitidine Injection Oncology
- Azacitidine, Injection, 100 mg (NDC 16729-306-10)
- Azacitidine, Injection, 100 mg (NDC 43598-305-62)Available to existing customers
- Azacitidine, Injection, 100 mg (NDC 68001-313-56)Estimated recovery: TBD
- Azacitidine, Injection, 100 mg (NDC 72485-201-01)Estimated recovery: TBD
- Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)Product temporarily on backorder. Additional lots will be available the end of October 2026.
- Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)Discontinuation of the manufacture of the drug
- Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)
- Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)On backorder. Recovery: TBD. Check wholesalers for inventory
- Vidaza, Injection, 100 mg (NDC 59572-102-01)
Bacitracin Ophthalmic Ointment Anti-Infective, Ophthalmology
- Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)Shortage is estimated for 15 additional months
Bupivacaine Hydrochloride Injection Anesthesia
- Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL 5mg / 1mL (NDC 72266-263-10)Distributed by Fosun Pharma USA Inc.
- Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)
- Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)Check wholesalers for inventory
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)Check wholesalers for inventory
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)Check wholesalers for inventory
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)Estimated recovery: June 2027
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)Estimated recovery: June 2027
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)Meitheal Pharmaceuticals is distributor/labeler
- Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)Meitheal Pharmaceuticals is distributor/labeler
- Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)
- Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)
And 42 more presentations.
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection Anesthesia
- Bupivacaine Hydrochloride with Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Bupivacaine Hydrochloride with Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Bupivacaine Hydrochloride with Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Bupivacaine Hydrochloride with Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Bupivacaine Hydrochloride with Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Bupivacaine Hydrochloride with Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC...Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC...
- Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC...
- Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC...
- Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC...
- Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC...
- Marcaine with Epinephrine, Injection, Marcaine™ 0.25% 125 mg/50 mL (2.5 mg/mL) with Epinephrine 1:200,000 (as bitartrate) Multiple Dose...
- Marcaine with Epinephrine, Injection, Marcaine™ 0.25% 25 mg/10 mL (2.5 mg/mL) with Epinephrine 1:200,000 (as bitartrate) Single Dose Vial...
- Marcaine with Epinephrine, Injection, Marcaine™ 0.25% 75 mg/30 mL (2.5 mg/mL) with Epinephrine 1:200,000 (as bitartrate) Single Dose Vial...
And 11 more presentations.
Carboplatin Injection Oncology
- Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)Estimated recovery: December 2028
- Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)Estimated recovery: January 2027
- Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)
- Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)Estimated recovery: March 2027
- Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)Discontinuation of the manufacture of the drug and SKU is non-Exempt by FDA
- Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)Discontinuation of the manufacture of the drug and SKU is non-Exempt by FDA
- Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)Discontinuation of the manufacture of the drug and SKU is non-Exempt by FDA
- Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)Discontinuation of the manufacture of the drug and SKU is non-Exempt by FDA
- Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)Next release December 2026. Check wholesalers for inventory.
- Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)Next Delivery: December 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug
- Carboplatin, Injection, 150 mg/15 mL (NDC 69339-365-15)Wholesaler & Distributor through Marketing partner (Natco Pharma USA LLC)
- Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)Distributed by BPI Labs, LLC
- Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
And 20 more presentations.
Cefotaxime Sodium Powder, for Solution Anti-Infective, Pediatric
- Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)Estimated recovery: TBD
- Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)
- Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)Estimated recovery: TBD
- Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)Estimated recovery: TBD
- Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)
- Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)Estimated recovery: TBD
Clindamycin Phosphate Injection Anti-Infective
- Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26)Discontinuation of the manufacture of the drug
- Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02)Discontinuation of the manufacture of the drug
- Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26)Discontinuation of the manufacture of the drug
- Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04)Discontinuation of the manufacture of the drug
- Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18)Discontinuation of the manufacture of the drug
- Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06)Discontinuation of the manufacture of the drug
- Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)
- Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)Civica Label
- Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)
- Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)Civica Label
- Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)
- Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)Selling through remaining short-dated inventory (Dec 2026).
And 8 more presentations.
Conivaptan Hydrochloride Injection Cardiovascular
- Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)Estimated recovery: TBD
Cromolyn Sodium Concentrate Pulmonary/Allergy
- Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)
- Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)
- Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)No longer manufactured, some supplies still available in supply chain. Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2
- Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)No longer manufactured, some supplies still available in supply chain. Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300
- Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195
- Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)
Desmopressin Acetate Spray Hematology
- Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)Estimated recovery: TBD
- Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)Replenishment expected mid to late November 2026
- Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)Estimated recovery: TBD
- Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)Estimated recovery: TBD
Dexamethasone Sodium Phosphate Injection Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology
- Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)Check wholesalers for inventory
- Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)
- Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)Product will be made available as it is released.
- Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)Check wholesalers for inventory
- Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)Check wholesalers for inventory
- Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)
- Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)
- Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)Next release January 2027. Check wholesalers for inventory.
- Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)Next release January 2027. Check wholesalers for inventory.
- Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)Product temporarily on backorder. Additional lots will be available in the November 2026 timeframe.
- Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)Additional product will be made available as it is released.
- Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)Check wholesalers for inventory
- Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)Check wholesalers for inventory
- Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)Next release November 2026. Check wholesalers for inventory.
- Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)
And 4 more presentations.
Dexmedetomidine Hydrochloride Injection Anesthesia
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)Additional product will be made available as it is released.
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)Discontinuation of the manufacture of the drug
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)Discontinuation of the manufacture of the drug
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)Please check wholesalers for inventory
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)Marketed by WG Critical Care
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)Marketed by WG Critical Care
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)Check wholesalers for inventory
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)Estimated recovery: TBD
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)
- Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)
- Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)Discontinuation of the manufacture of the drug; Distributed by Avenacy; Contact information: 877-283-6229
- Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)Distributed by Wilshire Pharmaceuticals, Inc.
- Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)Distributed by Civica
And 43 more presentations.
Dextrose Monohydrate 10% Injection Endocrinology/Metabolism, Gastroenterology, Other, Pediatric
- Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)On Allocation. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)On Allocation. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)On Allocation. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)Product discontinued. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)
- Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)
- Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)
- Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)Check wholesalers for inventory
- Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)Check wholesalers for inventory
- Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)Check wholesalers for inventory
- Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)
- Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)
- Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)
Dextrose Monohydrate 5% Injection Endocrinology/Metabolism, Gastroenterology, Other, Pediatric
- Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)On Allocation. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)On Allocation. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)On Allocation. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)On Allocation. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
And 21 more presentations.
Dextrose Monohydrate 50% Injection Endocrinology/Metabolism, Gastroenterology, Pediatric
- Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)Next Delivery: November 2026; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
- Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)
Dextrose Monohydrate 70% Injection Endocrinology/Metabolism, Gastroenterology, Other, Pediatric
- DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)
- Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)
Dobutamine Hydrochloride Injection Cardiovascular, Pediatric, Renal
- Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (4 mg/mL) (NDC 0409-1100-10)
- Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)
- Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)
- Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (1 mg/mL) (NDC 0409-0025-10)
- Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)
- Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (2 mg/mL) (NDC 0409-0151-10)
- Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988
- Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)
- Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)
- Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
Dopamine Hydrochloride Injection Cardiovascular
- Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)
- Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)Estimated recovery: November 2026
- Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)
- Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)
- Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)
- Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)
- Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
- Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)Product temporarily on backorder. Additional lots will be available in the February 2027 timeframe.
- Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
- Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)Next Delivery and Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
Echothiophate Iodide Ophthalmic Solution Ophthalmology
- Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)Available through limited distribution by Walgreens Specialty Pharmacy.
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection Anesthesia, Pediatric
- Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)Next Delivery: February 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)Next Delivery: January 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)Limited Supply Available. Next Delivery: August 2027; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)Limited Supply Available. Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)Check wholesalers for inventory
- Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)Check wholesalers for inventory
- Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)Check wholesalers for inventory
- Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)Check wholesalers for inventory
- Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)Check wholesalers for inventory
And 7 more presentations.
Etomidate Injection Anesthesia
- Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)
- Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)Novaplus label
- Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)Novaplus label
- Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)Additional product will be made available as it is released.
- Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)Additional product will be made available as it is released.
- Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)
- Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)
- Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.
- Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.
- Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)Distributed by Civica
- Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)Distributed by Civica
- Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586
- Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586
- Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)On backorder. Recovery: TBD. Check wholesalers for inventory
And 3 more presentations.
Fentanyl Citrate Injection Analgesia/Addiction, Pediatric
- Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)Check wholesalers for inventory
- Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)Check wholesalers for inventory
- Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)Check wholesalers for inventory
- Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)Next release December 2026. Check wholesalers for inventory.
- Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)Next release December 2026. Check wholesalers for inventory.
- Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)
- Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026
- Fentanyl Citrate, Injection, 2,500 mcg/50 mL (50 mcg/mL) Single Dose Glass Fliptop Vial (NDC 0409-9094-55)
- Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026
- Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)
- Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
- Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
- Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
- Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
- Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
And 5 more presentations.
Flurazepam Hydrochloride Capsule Neurology, Other
- Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.
- Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)
- Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)
- Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.
- Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)
- Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)
Furosemide Injection Cardiovascular
- Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)Discontinuation of the manufacture of the drug and SKU is non-Exempt by FDA
- Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)Discontinuation of the manufacture of the drug and SKU is non-Exempt by FDA
- Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)Discontinuation of the manufacture of the drug and SKU is non-Exempt by FDA
- Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)
- Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)
- Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)
- Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product
- Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product
- Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
- Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)
- Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)
- Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)
- Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)Check wholesalers for inventory
- Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)Next release November 2026. Check wholesalers for inventory.
- Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)7 mos expiry (6/30/2027) available on request. Check wholesaler for inventory.
And 12 more presentations.
Furosemide Oral Solution Cardiovascular
- Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)
- Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)
- Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)
Heparin Sodium Injection Hematology
- Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)Estimated recovery: late Q1 2027; Manufacturing delays
- Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)Estimated recovery: late Q1 2027; Manufacturing delays
- Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)Estimated recovery: January 2027
- Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)
- Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)
- Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)
- Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)Next release November 2026. Check wholesalers for inventory.
- Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)Next release November 2026. Check wholesalers for inventory.
Hydromorphone Hydrochloride Injection Analgesia/Addiction
- Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)Next release November 2026. Check wholesalers for inventory.
- Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)Next release November 2026. Check wholesalers for inventory.
- Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)Next release November 2026. Check wholesalers for inventory.
- Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)Next release not available at this time. Check wholesalers for inventory.
- Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)Next release November 2026. Check wholesalers for inventory.
- Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)Limited Supply Available. Next Delivery and Estimated Recovery: December 2026
- Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)
- Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)
- Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)
- Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)Estimated recovery: November 2026
- Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)Check wholesalers for inventory
- Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)Check wholesaler for inventory
And 11 more presentations.
Hydroxocobalamin Injection Other
- Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches...
- Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)Estimated recovery: mid-November 2026
Ifosfamide Injection Oncology, Pediatric
- IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)
- IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)
- Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)To place an order, please contact GlobalRX at [email protected] or (919) 245-8418
- Ifosfamide, Injection, 1 g/1 (NDC 63323-142-10)Check wholesalers for inventory
- Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)
- Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)
- Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
- Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
Isocarboxazid Tablet Psychiatry
- Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)Estimated recovery: TBD
Ketorolac Tromethamine Injection Analgesia/Addiction
- Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)Estimated recovery: December 2026
- Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)Next Delivery and Estimated Recovery: December 2027
- Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)Estimated recovery: TBD
- Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)
- Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)Estimated recovery: Mid-November 2026, Product in transit and expected to arrive week of Nov 12th
- Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)
- Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)Check wholesalers for inventory
- Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)Estimated recovery: TBD
- Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)
- Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
- Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)Estimated recovery: TBD
- Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)Estimated recovery: TBD
- Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)
- Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)
- Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)Product in transit with expected delivery in December 2026
And 10 more presentations.
Lidocaine Hydrochloride Injection Anesthesia, Pediatric
- Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)Distributed by Avenacy, LLC
- Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)
- Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)
- Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)
- Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)
- Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)
- Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)
- Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)Check wholesalers for inventory
- Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)
- Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)
- Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)
- Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)
- Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)
- Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)Next release December 2026. Check wholesalers for inventory.
And 50 more presentations.
Liraglutide Injection Endocrinology/Metabolism
- Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)
- Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)
- Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)Distributed by Teva
- Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)Distributed by Teva
- Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)Discontinuation of the manufacture of the drug
- Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)
- Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)
- Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
- Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)Estimated shortage duration: TBD
- Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)Estimated shortage duration: TBD
Lisdexamfetamine Dimesylate Capsule Psychiatry
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)Available on allocation
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)On allocation
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)Estimated recovery: TBD
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)
- Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)Estimated recovery: TBD
- Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)Available on allocation
- Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)
- Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)
- Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)
And 75 more presentations.
Lisdexamfetamine Dimesylate Tablet, Chewable Psychiatry
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)
- Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)
- Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)
- Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)
- Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)
And 3 more presentations.
Lorazepam Injection Neurology
- Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)Estimated recovery: TBD
- Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)Estimated recovery: TBD
- Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)Estimated recovery: TBD
- Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)Check wholesalers for inventory
- Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)
- Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)Limited Supply Available. Next Delivery and Estimated Recovery: June 2027
- Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)Estimated recovery: TBD
Meperidine Hydrochloride Injection Analgesia/Addiction
- Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)
- Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)
- Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)
- Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
Methotrexate Sodium Injection Rheumatology, Oncology
- Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)Check wholesaler for inventory
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)Estimated recovery: TBD
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)Estimated Recovery: Novemeber 2026
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)Estimated recovery: TBD
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)Short dated inventory with expiry of 8/31/2027 available; Estimated recovery: Jan 2027
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)
- Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)Check wholesaler for inventory
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) Multiple Dose Vial PREMIERProRx (NDC 61703-161-05)Next Delivery: July 2027; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
- Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)Additional lots will be available in the November 2026 timeframe. Short Dated Prodcut Available.
- Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.
Methylphenidate Film, Extended Release Psychiatry
- Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)Distributed by Padagis US LLC
- Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)Distributed by Padagis US LLC
- Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)Distributed by Padagis US LLC
- Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)Distributed by Padagis US LLC
Methylphenidate Hydrochloride Tablet, Extended Release Psychiatry
- Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)
- Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)
- Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)
- Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)
- Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)Allocation to current contracted customers
- Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)Currently not marketed
- Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)
- Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)
- Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)Allocation to current contracted customers
- Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)Currently not marketed
- Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)
- Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)Estimated recovery: November 2026
- Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)Allocation to current contracted customers
- Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)Currently not marketed
- Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)Estimated recovery: November 2026
And 19 more presentations.
Methylprednisolone Acetate Injection Rheumatology
- Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)
- Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)Next Delivery: November 2026; Estimated Recovery: December 2026
- Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026
- Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027
- Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)Next Delivery: November 2026; Estimated Recovery: December 2026
- Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)
- Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)
- Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)Limited Supply Available. Next Delivery and Estimated Recovery: December 2026
- Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)
- Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)Next supply due in March 2027
And 8 more presentations.
Metronidazole Injection Anti-Infective
- Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)
- Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)Labeler: Hospira Inc.
- Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)Discontinuation of the manufacture of the drug
- Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)Estimated recovery: November 2026; Marketed by Sagent Pharmaceuticals
Midazolam Hydrochloride Injection Anesthesia, Neurology
- Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)Next Delivery: December 2026; Estimated Recovery: March 2027
- Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)Next release December 2026. Check wholesalers for inventory.
- Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)Limited Supply Available. Next Delivery: December 2026; Estimated Recovery: June 2027
- Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)Next Estimated Delivery and Estimated Recovery: December 2026
- Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) Single Dose Glass Fliptop Vial Novaplus (NDC 0409-2305-50)Next Delivery: December 2027; Estimated Recovery: March 2028; Shortage per Manufacturer: Manufacturing Delay
- Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: March 2027
- Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)Next Delivery and Estimated Recovery: December 2026
- Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL Single Dose Glass Fliptop Vial Novaplus (NDC 0409-2308-49)
- Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)
- Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals
- Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)Estimated recovery: TBD
- Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)Check wholesalers for inventory
And 15 more presentations.
Morphine Sulfate Injection Analgesia/Addiction
- Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
- Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)On allocation
- Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)On allocation
- Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)
- Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)Check wholesalers for inventory
- Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)Discontinuation of the manufacture of the drug
- Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
- Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)Next release December 2026. Check wholesalers for inventory.
- Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)Check wholesalers for inventory
- Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)
And 9 more presentations.
Penicillin G Benzathine Injection Anti-Infective
- Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
- Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
- Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay
- Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)
Pentostatin Injection Oncology
- Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)Next Delivery and Estimated Recovery: December 2028
Promethazine Hydrochloride Injection Analgesia/Addiction, Gastroenterology, Pediatric, Pulmonary/Allergy
- Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)Estimated recovery: TBD
- Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)Estimated recovery: TBD
- Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
- Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)
- Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)Estimated recovery: TBD
- Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)Estimated recovery: TBD
Propranolol Hydrochloride Injection Cardiovascular
- Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)Estimated recovery: TBD
- Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)Next release: November 2026. Check wholesalers for inventory.
Quinapril Hydrochloride Tablet Cardiovascular
- Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)Not available. Long-term backorder for all NDCs. No estimated release date at this time.
- Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)
- Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)Discontinuation of the manufacture of the drug
- Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)Estimated recovery: TBD
- Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)Not available. Long-term backorder for all NDCs. No estimated release date at this time.
- Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)
- Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)Estimated recovery: TBD
- Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)Not available. Long-term backorder for all NDCs. No estimated release date at this time.
- Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)
- Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)Discontinuation of the manufacture of the drug
- Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)Estimated recovery: TBD
- Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)Not available. Long-term backorder for all NDCs. No estimated release date at this time.
- Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)
- Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)Discontinuation of the manufacture of the drug
- Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)Estimated recovery: TBD
Quinapril/Hydrochlorothiazide Tablet Cardiovascular
- Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)Discontinuation of the manufacture of the drug
- Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)Discontinuation of the manufacture of the drug
- Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)Discontinuation of the manufacture of the drug
- Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)
- Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)
- Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)
Remifentanil Hydrochloride Injection Analgesia/Addiction
- Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)Estimated recovery: TBD
- Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)Check wholesalers for inventory
- Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)Check wholesalers for inventory
- Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)Check wholesalers for inventory
- Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)Estimated recovery: TBD
- Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)Estimated recovery: TBD
- Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)
- Ultiva, Injection, 2 mg (NDC 72078-035-02)
- Ultiva, Injection, 5 mg (NDC 72078-036-05)
Rifampin Capsule Anti-Infective
- Rifampin, Capsule, 150 mg (NDC 42806-801-01)Discontinuation of the manufacture of the drug
- Rifampin, Capsule, 150 mg (NDC 42806-801-30)
- Rifampin, Capsule, 150 mg (NDC 68180-658-06)
- Rifampin, Capsule, 300 mg (NDC 42806-799-01)Discontinuation of the manufacture of the drug
- Rifampin, Capsule, 300 mg (NDC 42806-799-05)Discontinuation of the manufacture of the drug
- Rifampin, Capsule, 300 mg (NDC 42806-799-30)Discontinuation of the manufacture of the drug
- Rifampin, Capsule, 300 mg (NDC 42806-799-60)
- Rifampin, Capsule, 300 mg (NDC 68180-659-06)
- Rifampin, Capsule, 300 mg (NDC 68180-659-07)
Rifampin Injection Anti-Infective
- Rifadin, Injection, 600 mg (NDC 0068-0597-01)Discontinuation of the manufacture of the drug
- Rifadin, Injection, 600 mg (NDC 0068-0660-50)
- Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)Discontinuation of the manufacture of the drug
- Rifampin, Injection, 600 mg (NDC 63323-351-20)Check wholesalers for inventory
- Rifampin, Injection, 600 mg (NDC 67457-445-60)Estimated recovery: Q4 2026
Riluzole Oral Suspension Neurology
- Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)
- Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)
- Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)
- Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)Estimated recovery: TBD
Rocuronium Bromide Injection Anesthesia
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)Additional lots will be available. Product will be made available as it is released.
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)Additional lots will be available. Product will be made available as it is released.
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)Next release December 2026. Check wholesalers for inventory.
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)Check wholesalers for inventory
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)Estimated recovery: TBD
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)Check wholesalers for inventory
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)Check wholesalers for inventory
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)
- Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)
- Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)
And 11 more presentations.
Ropivacaine Hydrochloride Injection Anesthesia
- Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)Estimated recovery: TBD
- Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)
- Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)Estimated recovery: TBD
- Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)
- Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)Estimated recovery: TBD
- Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)Next release not available at this time. Check wholesalers for inventory.
- Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)Estimated recovery: TBD
- Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)Check wholesalers for inventory
- Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)Estimated recovery: TBD
- Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)Estimated recovery: TBD
- Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)
- Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)Check wholesalers for inventory
- Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)
- Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)
- Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)
And 34 more presentations.
Sodium Acetate Injection Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition
- Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)
- Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)
- Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)Additional lots will be available. Product will be made available as it is released.
- Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)
- Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)
- Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)
- Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)
- Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)
- Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)
- Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)Next release November 2026. Check wholesalers for inventory.
- Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)
- Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)
- Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)Additional lots will be available. Product will be made available as it is released.
- Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)
- Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)Estimated recovery: TBD
Sodium Bicarbonate Injection Endocrinology/Metabolism, Gastroenterology, Pediatric
- Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)Limited Supply Available. Next Delivery: July 2027; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
- Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027
- Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)
- Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)Check wholesalers for inventory.
- Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)
- Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay
- Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)
- Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)
- Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)Check wholesalers for inventory
- Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)Available on allocation
- Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)
Sterile Water Injection Other
- Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)
- Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)Check wholesalers for inventory
- Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)Next release November 2026. Check wholesalers for inventory.
- Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)Next release December 2026. Check wholesalers for inventory.
- Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)
- Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)
- Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)
- Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)
- Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)Small amount of inventory available with 12/31/2026 dating
- Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.
- Sterile Water, Injection, 10 mL Single Dose Plastic Fliptop Vial Novaplus (NDC 0409-0024-10)
- Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)
- Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)Check wholesalers for inventory
Sterile Water Irrigant Gastroenterology, Other, Pediatric
- Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)
- Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)
- Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.
- Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)
- Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)
- Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)Estimated Recovery: February 2027
Streptozocin Powder, For Solution Oncology
- Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)
- Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)Estimated recovery: TBD
Sufentanil Citrate Injection Analgesia/Addiction, Pediatric
- Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)Not currently manufactured
- Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)Not currently manufactured
- Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)Not currently manufactured
- Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
Technetium TC-99M Pyrophosphate Kit Injection Medical Imaging
- CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)Estimated recovery: TBD
- CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)Estimated recovery: TBD
- Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)On allocation
Triamcinolone Hexacetonide Injection Rheumatology
- Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)
Valproate Sodium Injection Neurology
- Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)Next release November 2026. Check wholesalers for inventory.
- Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)Additional lots will be available. Product will be made available as it is released.
Activated Charcoal Oral Suspension Other
- Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-25)Discontinuation of the manufacture of the drug
- Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-74)Discontinuation of the manufacture of the drug
- Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-76)Discontinuation of the manufacture of the drug
- Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-74)Discontinuation of the manufacture of the drug
- Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-76)Discontinuation of the manufacture of the drug
Adalimumab-adaz Injection Rheumatology
- Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64)Equivalent Sandoz format is available.
- Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36)Equivalent Sandoz format is available.
- Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68)Equivalent Sandoz format is available.
- Hyrimoz, Injection, Kit (NDC 61314-517-36)Equivalent Sandoz format is available.
- Hyrimoz, Injection, Kit (NDC 61314-531-64)Equivalent Sandoz format is available.
Allopurinol Tablet Oncology, Renal, Rheumatology
- Allopurinol, Tablet, 100 mg (NDC 0591-5543-01)Discontinuation of the manufacture of the drug
- Allopurinol, Tablet, 100 mg (NDC 0591-5543-10)Discontinuation of the manufacture of the drug
- Allopurinol, Tablet, 300 mg (NDC 0591-5544-01)Discontinuation of the manufacture of the drug
- Allopurinol, Tablet, 300 mg (NDC 0591-5544-05)Discontinuation of the manufacture of the drug
Alteplase Injection Cardiovascular, Hematology, Neurology
- Activase, Injection, 1 KIT in 1 CARTON (50242-085-27) * 100 mL in 1 VIAL, SINGLE-USE * 100 mL in 1 VIAL, SINGLE USE (NDC 50242-085-27)Discontinuation of the 100mg vial configuration
Ampicillin Sodium Injection Anti-Infective
- Ampicillin Sodium, Injection, 1 g (NDC 0781-9404-95)Discontinuation of private label only
- Ampicillin Sodium, Injection, 1 g (NDC 0781-9412-92)Discontinuation of private label only
- Ampicillin Sodium, Injection, 10 g (NDC 0781-9409-95)Discontinuation of private label only
- Ampicillin Sodium, Injection, 2 g (NDC 0781-9408-95)Discontinuation of private label only
- Ampicillin Sodium, Injection, 2 g (NDC 0781-9413-92)Discontinuation of private label only
Anagrelide Hydrochloride Capsule Hematology
- Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60)A business decision was made to discontinue manufacture of the drug.
- Anagrelide Hydrochloride, Capsule, 1 mg (NDC 0172-5240-60)A business decision was made to discontinue manufacture of the drug.
Aprepitant Oral Powder for Suspension Gastroenterology
- Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03)To be discontinued in approximately early-September 2026.
Arsenic Trioxide Injection Oncology
- Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 50742-438-10)A business decision was made to discontinue manufacture of the drug.
- Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 63323-637-10)Discontinuation of the manufacture of the drug
Aspirin Suppository Analgesia/Addiction, Cardiovascular
- Aspirin, Suppository, 300 mg (NDC 0574-7034-12)Discontinuation of the manufacture of the drug
Azithromycin Injection Anti-Infective
- Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83)Discontinuation of the manufacture of the drug.
Azithromycin Tablet Anti-Infective
- Zithromax, Tablet, 250 mg (NDC 0069-4061-01)Discontinuation of the manufacture of the drug
- Zithromax, Tablet, 500 mg (NDC 0069-3070-30)Discontinuation of the manufacture of the drug
Belladonna and Opium Suppository Analgesia/Addiction
- Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-04)Discontinuation of the manufacture of the drug
- Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-12)Discontinuation of the manufacture of the drug
- Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-04)Discontinuation of the manufacture of the drug
- Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-12)Discontinuation of the manufacture of the drug
Bendamustine Hydrochloride Injection, Solution Oncology
- Treanda, Injection, Solution, 25 mg/5 mL, 1 vial, Single-Dose in 1 carton (NDC 63459-390-08)A business decision has been made to discontinue manufacture of the drug.
Benztropine Mesylate Injection Neurology
- Benztropine Mesylate, Injection, 1 mg/1 mL (NDC 63323-970-02)Discontinuation of the manufacture of the drug
Calcitriol Capsule Endocrinology/Metabolism
- Calcitriol, Capsule, .25 ug (NDC 0093-7352-01)A business decision was made to discontinue manufacture of the drug
- Calcitriol, Capsule, .5 ug (NDC 0093-7353-01)A business decision was made to discontinue manufacture of the drug
Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution Renal
- DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448...A business decision was made to discontinue manufacture of the drug.
- DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448...A business decision was made to discontinue manufacture of the drug.
- DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448...A business decision was made to discontinue manufacture of the drug.
- DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448...A business decision was made to discontinue manufacture of the drug.
- DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448...A business decision was made to discontinue manufacture of the drug.
- DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448...A business decision was made to discontinue manufacture of the drug.
- DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL...A business decision was made to discontinue manufacture of the drug.
- DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL...A business decision was made to discontinue manufacture of the drug.
- DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL...A business decision was made to discontinue manufacture of the drug.
- DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL...A business decision was made to discontinue manufacture of the drug.
- DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL...A business decision was made to discontinue manufacture of the drug.
- DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL...A business decision was made to discontinue manufacture of the drug.
- DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL...A business decision was made to discontinue manufacture of the drug.
- DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL...A business decision was made to discontinue manufacture of the drug.
- DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100...A business decision was made to discontinue manufacture of the drug.
And 3 more presentations.
Carbamazepine Capsule, Extended Release Neurology
- Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12)Discontinuation of the manufacture of the drug
- Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12)Discontinuation of the manufacture of the drug
- Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12)Discontinuation of the manufacture of the drug
Caspofungin Acetate Injection Anti-Infective
- Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94)Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
- Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94)Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
- Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10)Discontinuation of the manufacture of the drug
Cefazolin in Dextrose Injection Anti-Infective
- Cefazolin in Dextrose, Injection, 1g/50 mL (NDC 0338-3503-41)Discontinuation of the manufacture of the drug
- Cefazolin in Dextrose, Injection, 2g/100mL (NDC 0338-3508-41)Discontinuation of the manufacture of the drug
- Cefazolin in Dextrose, Injection, 3g/150mL (NDC 0338-0096-06)Discontinuation of the manufacture of the drug
Cefepime Hydrochloride Injection Anti-Infective
- Cefepime Hydrochloride in Plastic Container, Injection, 1g/50 mL (NDC 0338-1301-41)Discontinuation of the manufacture of the drug
- Cefepime Hydrochloride in Plastic Container, Injection, 2g/100mL (NDC 0338-1301-48)Discontinuation of the manufacture of the drug
- Cefepime Hydrochloride, Injection, 1 g (NDC 63323-326-20)Discontinuation of the manufacture of the drug.
- Cefepime Hydrochloride, Injection, 2 g (NDC 63323-340-20)Discontinuation of the manufacture of the drug.
Ceftazidime Injection Anti-Infective
- Tazicef, Injection, 1 g (NDC 0409-5092-16)Discontinuation of the manufacture of the drug
- Tazicef, Injection, 2 g (NDC 0409-5093-11)Discontinuation of the manufacture of the drug
Ceftriaxone Sodium Injection Anti-Infective
- Ceftriaxone Sodium in Plastic Container, Injection, 1g/50mL (NDC 0338-5002-41)Discontinuation of the manufacture of the drug
- Ceftriaxone Sodium in Plastic Container, Injection, 2g/100 mL (NDC 0338-5003-41)Discontinuation of the manufacture of the drug
Chlorothiazide Oral Suspension Cardiovascular
- Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12)
Ciprofloxacin Hydrochloride and Hydrocortisone Otic Suspension/Drops Anti-Infective
- Cipro, Otic Suspension/Drops, 0.2% base, 1% (NDC 66758-087-70)Discontinuation of the manufacturing of NDC 66758-087-70. Authorized generic is available under new NDC 0781-6218-70
Cisatracurium Besylate Injection Analgesia/Addiction
- Cisatracurium Besylate, Injection, 10 mg/5ml (2 mg/mL) Single Dose Vial (NDC 0409-1098-02)Supply expected to exhaust November 2026; Discontinuation of the manufacture of the drug
- Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01)Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug
- Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug
Clindamycin Hydrochloride Capsule Anti-Infective
- Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02)Discontinuation of the manufacture of the drug
- Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14)Discontinuation of the manufacture of the drug
- Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02)Discontinuation of the manufacture of the drug
Clindamycin Palmitate Hydrochloride Injection Anti-Infective
- Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19)Discontinuation of the manufacture of the drug
Crinecerfont Capsule Endocrinology/Metabolism
- Crenessity, Capsule, 25 mg (NDC 70370-5025-1)Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will...
Dacomitinib Tablet Oncology
- Vizimpro, Tablet, 15 mg (NDC 0069-0197-30)Discontinuation of the manufacture of the drug
- Vizimpro, Tablet, 30 mg (NDC 0069-1198-30)Discontinuation of the manufacture of the drug
- Vizimpro, Tablet, 45 mg (NDC 0069-2299-30)Discontinuation of the manufacture of the drug
Dapsone Gel Dermatology
- Dapsone, Gel, 7.5% (NDC 69238-1627-6)Discontinuation of the manufacture of the drug
Daptomycin Injection Anti-Infective
- Daptomycin, Injection, 500 mg/10 mL (NDC 0143-9378-01)Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc.
- Daptomycin, Injection, 500 mg/10 mL (NDC 57884-3151-1)Discontinuation of the manufacture of the drug
Decitabine Injection Oncology
- Decitabine, Injection, 50 mg (NDC 50742-430-01)Discontinuation of the manufacture of the drug
- Decitabine, Injection, 50 mg (NDC 68001-573-41)Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug
Dehydrated Alcohol Injection, Solution Cardiovascular
- Dehydrated Alcohol, Injection, Solution, 1 mL/1 mL (10 pack) (NDC 16729-710-45)Accord is transitioning to the 5-pack configuration (NDC 16729-710-53).
Desflurane Liquid for Inhalation Anesthesia
- Desflurane, Liquid for Inhalation, 240 mL/240 mL (NDC 0781-6172-86)Discontinuation of the manufacture of the drug; Distributed by Sandoz, Inc.
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution Renal
- DELFLEX, Solution, 18.4 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 46163-212-95)A business decision was made to discontinue manufacture of the drug.
Diclofenac Sodium Tablet, Delayed Release Musculoskeletal, Rheumatology
- Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-06)A business decision was made to discontinue manufacture of the drug.
- Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-11)A business decision was made to discontinue manufacture of the drug.
- Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-96)A business decision was made to discontinue manufacture of the drug.
- Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-06)A business decision was made to discontinue manufacture of the drug.
- Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-11)A business decision was made to discontinue manufacture of the drug.
- Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-96)A business decision was made to discontinue manufacture of the drug.
Diltiazem Hydrochloride Injection Cardiovascular
- Diltiazem Hydrochloride, Injection, 100 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-4350-03)Discontinuation of the manufacture of the drug
Disopyramide Phosphate Capsule, Extended Release Cardiovascular
- Norpace CR, Capsule, Extended Release, 100 mg (NDC 0025-2732-31)Discontinuation of the manufacture of the drug
- Norpace CR, Capsule, Extended Release, 150 mg (NDC 0025-2742-31)Discontinuation of the manufacture of the drug
Docetaxel Injection Oncology
- Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08)A business decision was made to discontinue manufacture of the drug.
- Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16)A business decision was made to discontinue manufacture of the drug.
Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release Neurology
- Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 14 mg (NDC 69238-1248-3)Discontinuation of the manufacture of the drug
- Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 28 mg (NDC 69238-1247-3)Discontinuation of the manufacture of the drug
Doxercalciferol Injection Endocrinology/Metabolism
- Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1)Discontinuation of the manufacture of the drug
- Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1)Discontinuation of the manufacture of the drug
- Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1)Discontinuation of the manufacture of the drug
Doxycycline Hyclate Tablet Anti-Infective
- Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-02)Discontinuation of the manufacture of the drug
- Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-13)Discontinuation of the manufacture of the drug
Doxycycline Hyclate Tablet, Delayed Release Anti-Infective
- Doxycycline Hyclate, Tablet, Delayed Release, 200 mg (NDC 0591-4575-60)Discontinuation of the manufacture of the drug
- Doxycycline Hyclate, Tablet, Delayed Release, 50 mg (NDC 0591-4550-22)Discontinuation of the manufacture of the drug
Doxylamine Succinate and Pyridoxine Hydrochloride Tablet, Delayed Release Other
- Doxylamine Succinate and Pyridoxine Hydrochloride, Tablet, Delayed Release, 10 mg; 10 mg (NDC 0378-4615-01)A business decision was made to discontinue manufacture of the drug.
Emtricitabine Capsule Anti-Infective
- Emtriva, Capsule, 200 mg (NDC 61958-0601-1)Product expected to be available until March 2027
Emtricitabine Oral Solution Anti-Infective
- Emtriva, Oral Solution, 10 mg/1 mL (NDC 61958-0602-1)Product expected to be available until March 2027
Enoxaparin Sodium Injection Hematology
- Enoxaparin Sodium, Injection, 100 mg/1 mL (NDC 0955-1010-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 120 mg/.8 mL (NDC 0955-1012-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 150 mg/1 mL (NDC 0955-1015-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 30 mg/.3 mL (NDC 0955-1003-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 300 mg/3 mL (NDC 0955-1016-01)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 40 mg/.4 mL (NDC 0955-1004-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 60 mg/.6 mL (NDC 0955-1006-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 80 mg/.8 mL (NDC 0955-1008-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 100 mg/1 mL (NDC 0075-0623-00)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 100 mg/1 mL (NDC 0075-8020-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 120 mg/.8 mL (NDC 0075-2912-01)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 120 mg/.8 mL (NDC 0075-8022-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 150 mg/1 mL (NDC 0075-2915-01)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 150 mg/1 mL (NDC 0075-8025-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 30 mg/.3 mL (NDC 0075-0624-30)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
And 9 more presentations.
Etravirine Tablet Antiviral
- Etravirine, Tablet, 100 mg (NDC 10147-0570-1)Discontinuation of the manufacture of the drug
- Intelence, Tablet, 100 mg (NDC 59676-570-01)Discontinuation of the manufacture of the drug
Everolimus Tablet Transplant
- Everolimus, Tablet, .25 mg (NDC 49884-158-02)A business decision was made to withdraw from sale.
- Everolimus, Tablet, .5 mg (NDC 49884-159-02)A business decision was made to withdraw from sale.
- Everolimus, Tablet, .75 mg (NDC 49884-160-02)A business decision was made to withdraw from sale.
- Everolimus, Tablet, 1 mg (NDC 49884-283-02)A business decision was made to withdraw from sale.
- Everolimus, Tablet, 10 mg (NDC 0093-7769-24)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 10 mg (NDC 49884-128-91)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 2.5 mg (NDC 49884-119-91)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 5 mg (NDC 0093-7767-24)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 5 mg (NDC 49884-125-91)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 7.5 mg (NDC 49884-127-91)Discontinuation of the manufacture of the drug
Felodipine Tablet, Extended Release Cardiovascular
- Felodipine, Tablet, Extended Release, 2.5 mg (NDC 0603-3581-21)Discontinuation in the manufacturing of the drug product
- Felodipine, Tablet, Extended Release, 2.5 mg (NDC 0603-3581-28)Discontinuation in the manufacturing of the drug product
- Felodipine, Tablet, Extended Release, 5 mg (NDC 0603-3582-21)Discontinuation in the manufacturing of the drug product
- Felodipine, Tablet, Extended Release, 5 mg (NDC 0603-3582-28)Discontinuation in the manufacturing of the drug product
Felodipine Tablet, Film Coated, Extended Release Cardiovascular
- Felodipine, Tablet, Film Coated, Extended Release, 10 mg (NDC 0603-3583-21)Discontinuation in the manufacturing of the drug product
- Felodipine, Tablet, Film Coated, Extended Release, 10 mg (NDC 0603-3583-28)Discontinuation in the manufacturing of the drug product
Fluocinonide Ointment Dermatology
- Fluocinonide, Ointment, .5 mg/1 g (NDC 0093-0264-15)Discontinuation of the manufacture of the drug
- Fluocinonide, Ointment, .5 mg/1 g (NDC 0093-0264-30)Discontinuation of the manufacture of the drug
- Fluocinonide, Ointment, .5 mg/1 g (NDC 0093-0264-92)Discontinuation of the manufacture of the drug
Fluticasone Propionate and Salmeterol Xinafoate Aerosol, Metered Pulmonary/Allergy
- Advair HFA, Aerosol, Metered, 115 ug; 21 ug (NDC 0173-0716-22)The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.
- Advair HFA, Aerosol, Metered, 230 ug; 21 ug (NDC 0173-0717-22)The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.
- Advair HFA, Aerosol, Metered, 45 ug; 21 ug (NDC 0173-0715-22)The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.
Fluvastatin Sodium Tablet, Extended Release Cardiovascular
- Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-01)Discontinuation of the manufacture of the drug
- Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-31)Discontinuation of the manufacture of the drug
- Lescol XL, Tablet, Extended Release, 80 mg (NDC 66758-211-31)Discontinuation of the manufacture of the drug
Fosaprepitant Dimeglumine Injection Gastroenterology
- Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10)Discontinuation of the manufacture of the drug
Frovatriptan Succinate Tablet Neurology
- Frova, Tablet, 2.5 mg (NDC 63481-025-09)A business decision was made to discontinue manufacture of the drug.
Fulvestrant Injection Oncology
- Fulvestrant, Injection, 250 mg per 5mL (NDC 63323-715-05)Discontinuation of the manufacture of the drug
Gadobutrol Injection Medical Imaging
- Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-02)Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA
- Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-07)Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA
- Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-10)Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA
- Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-15)Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA
Gadoterate Meglumine Injection Medical Imaging
- Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-080-05)Discontinuation of the manufacture of the drug
- Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-082-10)Discontinuation of the manufacture of the drug
- Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-084-15)Discontinuation of the manufacture of the drug
- Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-086-20)Discontinuation of the manufacture of the drug
Gemfibrozil Tablet Endocrinology/Metabolism
- Lopid, Tablet, 600 mg (NDC 0071-0737-20)Discontinuation of the manufacture of the drug.
Glyburide Tablet Endocrinology/Metabolism
- Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53)A business decision was made to discontinue manufacture of the drug.
- Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01)A business decision was made to discontinue manufacture of the drug.
- Diabeta, Tablet, 5 mg (NDC 0093-9364-01)A business decision was made to discontinue manufacture of the drug.
- Diabeta, Tablet, 5 mg (NDC 0093-9364-10)A business decision was made to discontinue manufacture of the drug.
Glycerol Phenylbutyrate Oral Liquid Inborn Errors
- RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-06)Discontinuation in the manufacturing of the drug product
- RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-07)Discontinuation in the manufacturing of the drug product
Glycopyrrolate Injection Anesthesia
- Glycopyrrolate, Injection, .2 mg/1 mL (NDC 63323-578-01)Discontinuation of the manufacture of the drug
- Glycopyrrolate, Injection, 0.2 mg per 1 mL (NDC 65219-801-01)Discontinuation of the manufacture of the drug
- Glycopyrrolate, Injection, 0.4 mg per 2 mL (NDC 63323-578-02)Discontinuation of the manufacture of the drug
- Glycopyrrolate, Injection, 1 mg per 5 mL (NDC 63323-578-05)Discontinuation of the manufacture of the drug
Haloperidol Decanoate Injection Psychiatry
- Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-01)Discontinuation of the manufacture of the drug
- Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-05)Discontinuation of the manufacture of the drug
Hydrochlorothiazide Capsule Cardiovascular
- Microzide, Capsule, 12.5 mg (NDC 0591-0347-01)A business decision was made to discontinue manufacture of the drug.
- Microzide, Capsule, 12.5 mg (NDC 0591-0347-05)A business decision was made to discontinue manufacture of the drug.
Hydrocortisone Acetate Suppository Analgesia/Addiction, Other
- Hydrocortisone Acetate, Suppository, 25 mg (NDC 0574-7090-12)Discontinuation of the manufacture of the drug
- Hydrocortisone Acetate, Suppository, 30 mg (NDC 0574-7093-12)Discontinuation of the manufacture of the drug
Hydromorphone Hydrochloride Suppository Analgesia/Addiction
- Hydromorphone Hydrochloride, Suppository, 3 mg (NDC 0574-7224-06)Discontinuation of the manufacture of the drug
Hydroxychloroquine Sulfate Tablet Anti-Infective, Other, Rheumatology
- Hydroxychloroquine Sulfate, Tablet, 200 mg (NDC 0093-2401-01)Discontinuation of the manufacture of the drug
Icatibant Acetate Injection Hematology
- Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86)Discontinuation of the manufacturer of the drug
- Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93)Discontinuation of the manufacturer of the drug
Icosapent Ethyl Capsule Cardiovascular
- Icosapent Ethyl, Capsule, 1 g (NDC 60429-005-12)Discontinuation of the manufacture of the drug
- Icosapent Ethyl, Capsule, 1 g (NDC 61474-9711-1)Discontinuation of the manufacture of the drug
Idelalisib Tablet Oncology
- Zydelig, Tablet, 100 mg (NDC 61958-1701-1)Discontinuation in the manufacturing of the drug
- Zydelig, Tablet, 150 mg (NDC 61958-1702-1)Discontinuation in the manufacturing of the drug
Imipenem and Cilastatin Injection Anti-Infective
- Primaxin, Injection, 500mg (NDC 0006-3516-59)To be discontinued approximately 11/30/2026
Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection Anti-Infective
- RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)To be discontinued on or near late September 2026.
Insulin Glargine-aglr Injection Endocrinology/Metabolism
- Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday...
Insulin Lispro Injection Endocrinology/Metabolism
- Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05)A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday...
Insulin Lispro Protamine and Insulin Lispro Injection Endocrinology/Metabolism
- Humalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05)A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday...
Irinotecan Hydrochloride Injection Oncology
- Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05)A business decision was made to discontinue manufacture of the drug.
- Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02)A business decision was made to discontinue manufacture of the drug.
Iron Sucrose Injection Hematology
- Iron Sucrose, Injection, 50 mg/2.5 mL (NDC 67457-957-99)A business decision has been made to discontinue of 2.5mL presentation only. Continuity of supply is forecasted across all other presentations of Iron Sucrose: 67457-639-10 Iron Sucrose 20mg/mL 10mL SDV 5PK 67457-638-10...
Itraconazole Capsule Anti-Infective, Other
- Sporanox, Capsule, 100 mg (NDC 10147-1700-3)Discontinuation of the manufacture of the drug
- Sporanox, Capsule, 100 mg (NDC 50458-290-01)Discontinuation of the manufacture of the drug
- Sporanox, Capsule, 100 mg (NDC 50458-290-04)Discontinuation of the manufacture of the drug
Ivabradine Hydrochloride Tablet Cardiovascular
- Corlanor, Tablet, eq. 5 mg base (NDC 55513-800-60)Discontinuation of the manufacture of the drug product
- Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60)Discontinuation of the manufacture of the drug product
Ivabradine Solution Cardiovascular
- Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28)Discontinuation of the manufacture of the drug product
Ivermectin Tablet Anti-Infective
- STROMECTOL, Tablet, 3 mg (NDC 0006-0032-01)Product will be discontinued on 10/31/2026
Ketorolac Tromethamine Tablet Analgesia/Addiction
- Ketorolac Tromethamine, Tablet, 10 mg (NDC 0378-1134-01)Discontinuation of the manufacture of the drug
Lamivudine Tablet Antiviral
- Epivir, Tablet, 150 mg (NDC 49702-203-18)The anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug
- Epivir, Tablet, 300 mg (NDC 49702-204-13)The anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug
Lamotrigine Tablet, Extended Release Neurology
- Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11)Discontinuation of the manufacture of the drug
Leflunomide Tablet Rheumatology
- Arava, Tablet, 10 mg (NDC 0088-2160-30)Discontinuation of the manufacture of the drug
- Arava, Tablet, 100 mg (NDC 0088-2162-33)Discontinuation of the manufacture of the drug
- Arava, Tablet, 20 mg (NDC 0088-2161-30)Discontinuation of the manufacture of the drug
- Leflunomide, Tablet, 10 mg (NDC 0955-1735-30)Discontinuation of the manufacture of the drug
- Leflunomide, Tablet, 20 mg (NDC 0955-1737-30)Discontinuation of the manufacture of the drug
Leuprolide Acetate Injection Oncology
- Leuprolide Acetate, Injection, 14 mg/2.8 mL (1 mg/0.2 mL) (NDC 70121-2537-6)A business decision was made to discontinue manufacture of the drug.
Lincomycin Hydrochloride Injection Anti-Infective
- Lincocin, Injection, 10 mL multiple dose vial (NDC 0009-0107-04)Discontinuation of the manufacture of the drug
- Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04)Discontinuation of the manufacture of the drug
- Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6)A business decision was made to discontinue manufacture of the drug.
- Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2)A business decision was made to discontinue manufacture of the drug.
Lopinavir and Ritonavir Oral Solution Antiviral
- Kaletra, Oral Solution, 80 mg/1 mL; 20 mg/1 mL (NDC 0074-3956-46)Discontinuation of the manufacture of the drug
Lopinavir and Ritonavir Tablet Antiviral
- Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-0522-60)Discontinuation of the manufacture of the drug
- Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-3008-60)Discontinuation of the manufacture of the drug
- Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-4014-12)Discontinuation of the manufacture of the drug
- Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-6799-22)Discontinuation of the manufacture of the drug
Lorlatinib Tablet Oncology
- Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03)Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue to be manufactured; Discontinuation of the manufacture of this presentation
Maraviroc Solution Antiviral
- Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton (NDC 49702-260-55)The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026.
Medroxyprogesterone Acetate Tablet Urology
- PROVERA, Tablet, 10 mg (NDC 0009-0051-01)Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 2026.
- PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01)Discontinuation of the manufacture of the drug; Withdrawal from sale expected early October 2026.
Melphalan Hydrochloride Injection Oncology
- Melphalan Hydrochloride, Injection, Kit (NDC 63323-760-20)Discontinuation of the manufacture of the drug
Mesalamine Capsule, Extended Release Gastroenterology
- Mesalamine, Capsule, Extended Release, .375 g (NDC 0378-1375-78)Discontinuation of the manufacture of the drug
- Pentasa, Capsule, Extended Release, 250 mg (NDC 54092-189-81)Product is anticipated to be available until December 31, 2027
- Pentasa, Capsule, Extended Release, 500 mg (NDC 54092-191-12)Product is anticipated to be available until December 31, 2027
Metformin Hydrochloride Tablet, Extended Release Endocrinology/Metabolism
- Metformin Hydrochloride, Tablet, Extended Release, 1000 mg (NDC 0378-6001-91)A business decision was made was discontinue manufacture of the drug product.
- Metformin Hydrochloride, Tablet, Extended Release, 500 mg (NDC 0378-6002-91)A business decision was made was discontinue manufacture of the drug product.
Metoprolol Succinate Tablet, Extended Release Cardiovascular
- Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-11)A business decision was made to discontinue manufacture of the drug.
- Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-96)A business decision was made to discontinue manufacture of the drug.
- Metoprolol Succinate, Tablet, Extended Release, 200 mg (NDC 45963-678-11)A business decision was made to discontinue manufacture of the drug.
- Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-11)A business decision was made to discontinue manufacture of the drug.
- Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-96)A business decision was made to discontinue manufacture of the drug.
- Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-11)A business decision was made to discontinue manufacture of the drug.
- Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-96)A business decision was made to discontinue manufacture of the drug.
Micafungin Sodium Injection Anti-Infective
- Micafungin Sodium, Injection, 10 mg/1 mL (NDC 42023-229-10)A business decision was made to discontinue manufacture of the drug.
- Micafungin Sodium, Injection, 20 mg/1 mL (NDC 42023-230-10)A business decision was made to discontinue manufacture of the drug.
Mirikizumab-mrkz Injection Gastroenterology, Other
- Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.
- Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.
Molnupiravir Capsule Anti-Infective
- Lagevrio, Capsule, 200 mg (NDC 0006-5055-06)Discontinuation of the manufacture of the drug
- Lagevrio, Capsule, 200 mg (NDC 0006-5055-07)Discontinuation of the manufacture of the drug
- Lagevrio, Capsule, 200 mg (NDC 0006-5055-09)Discontinuation of the manufacture of the drug
Montelukast Sodium Tablet, Chewable Pulmonary/Allergy
- Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01)Discontinuation of the manufacture of the drug
Morphine Sulfate Suppository Analgesia/Addiction
- Morphine Sulfate, Suppository, 10 mg (NDC 0574-7112-12)Discontinuation of the manufacture of the drug
- Morphine Sulfate, Suppository, 20 mg (NDC 0574-7114-12)Discontinuation of the manufacture of the drug
- Morphine Sulfate, Suppository, 30 mg (NDC 0574-7116-12)Discontinuation of the manufacture of the drug
- Morphine Sulfate, Suppository, 5 mg (NDC 0574-7110-12)Discontinuation of the manufacture of the drug
Morphine Sulfate Tablet Analgesia/Addiction
- Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11)Discontinuation of the manufacture of the drug
- Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11)Discontinuation of the manufacture of the drug
Nebivolol Hydrochloride Tablet Cardiovascular
- Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-01)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-05)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-30)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-90)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-01)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-05)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-30)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-90)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-01)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-05)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-30)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-90)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-01)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-05)Discontinuation of the manufacture of the drug
- Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-30)Discontinuation of the manufacture of the drug
And 1 more presentations.
Neostigmine Methylsulfate Injection Analgesia/Addiction
- Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10)Discontinuation of the manufacture of the drug
Nilutamide Tablet Oncology
- Nilandron, Tablet, 150 mg (NDC 59212-111-14)Product to expire in March 2026; Discontinuation of the manufacture of the drug
- Nilandron, Tablet, 150 mg (NDC 66993-212-38)Product to expire in March 2026; Discontinuation of the manufacture of the drug
Nitrofurantoin Oral Suspension Anti-Infective, Other
- Nitrofurantoin, Oral Suspension, 25 mg/5 mL (NDC 69238-2512-9)Discontinuation of the manufacture of the drug
Nitroglycerin Ointment Analgesia/Addiction
- Rectiv, Ointment, 0.4% (NDC 58914-301-80)Discontinuation of the manufacture of the drug
Oxaliplatin Injection Oncology
- Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-10)Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
- Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-20)Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
- Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10)A business decision was made to discontinue manufacture of the drug.
- Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20)A business decision was made to discontinue manufacture of the drug.
Palbociclib Capsule Oncology
- Ibrance, Capsule, 100 mg (NDC 0069-0188-21)Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.
- Ibrance, Capsule, 75 mg (NDC 0069-0187-21)Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet NDC 0069-0284-03 will continue to be manufactured.
Palonosetron Hydrochloride Injection Gastroenterology
- Palonosetron Hydrochloride, Injection, .25 mg/5 mL (NDC 0703-4094-01)Discontinuation of the manufacture of the drug
Palovarotene Capsule Musculoskeletal
- SOHONOS, Capsule, 2.5 mg (NDC 15054-0025-1)Discontinuation of the manufacture of the drug
Pentamidine Isethionate Injection Anti-Infective
- Pentamidine Isethionate, Injection, 300 mg/3 mL (NDC 39822-3050-2)A business decision was made to discontinue manufacture of the drug.
Peritoneal Dialysis Solution Renal
- DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-206-94)The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2L, 5/cs (NDC 46163-206-92)The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-209-94)The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2L, 5/cs (NDC 49230-209-92)The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 46163-212-94)The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
- DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2L, 5/cs (NDC 46163-212-92)The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
Phenoxybenzamine Hydrochloride Capsule Cardiovascular
- Dibenzyline, Capsule, 10 mg (NDC 59212-001-01)Discontinuation of the manufacture of the drug
- Dibenzyline, Capsule, 10 mg (NDC 59212-001-02)Discontinuation of the manufacture of the drug
- Dibenzyline, Capsule, 10 mg (NDC 66993-066-02)Discontinuation of the manufacture of the drug
Pilocarpine Hydrochloride Ophthalmic Solution Ophthalmology
- Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-01)Discontinuation of the manufacture of the drug
- Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-03)Discontinuation of the manufacture of the drug
- Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-04)Discontinuation of the manufacture of the drug
- Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-05)Discontinuation of the manufacture of the drug
- Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-06)Discontinuation of the manufacture of the drug
Pindolol Tablet Cardiovascular
- Pindolol, Tablet, 10 mg (NDC 57664-656-88)Discontinuation of the manufacture of the drug; Expiry date of last distributed batch October 2026
- Pindolol, Tablet, 5 mg (NDC 57664-655-88)Discontinuation of the manufacture of the drug; Expiry date of last distributed batch January 2027
Piperacillin and Tazobactam Injection Anti-Infective
- Piperacillin and Tazobactam, Injection, 2.25 g vial (NDC 65219-434-20)Discontinuation of the manufacture of the drug
Plerixafor Injection Hematology
- Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12)A business decision was made to discontinue manufacture of the drug.
Podofilox Topical Gel Dermatology, Other
- Condylox , Topical Gel, 0.5% (NDC 0023-6118-03)Discontinuation of the manufacture of the drug
Podophyllum Resin Topical Tincture Dermatology
- Podocon 25, Topical Tincture, 1 mg/4 mL (NDC 0574-0601-15)Discontinuation of the manufacture of the drug
Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution Gastroenterology
- Plenvu, Oral Solution, KIT (NDC 65649-400-01)A business decision was made to discontinue manufacture of the drug.
Posaconazole Injection Anti-Infective
- Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01)Discontinuation of the manufacture of the drug
Potassium Chloride Tablet, Extended Release Endocrinology/Metabolism, Gastroenterology
- Potassium Chloride, Tablet, Extended Release, 10 meq (NDC 62037-710-01)Discontinuation of the manufacture of the drug
- Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-01)Discontinuation of the manufacture of the drug
- Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-05)Discontinuation of the manufacture of the drug
- Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-10)Discontinuation of the manufacture of the drug
Potassium Chloride, Sodium Chloride, Calcium Chloride, and Magnesium Chloride Injection, Solution Cardiovascular
- Cardioplegic Solution, Injection, Solution, 17.6 mg/100 mL; 325.3 mg/100 mL; 119.3 mg/100 mL; 643 mg/100 mL (NDC 65219-258-10)Discontinuation of the manufacture of the drug
Prazosin Hydrochloride Capsule Cardiovascular
- Minipress, Capsule, 1 mg (NDC 0069-4310-71)Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023
- Minipress, Capsule, 2 mg (NDC 0069-4370-71)Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023
- Minipress, Capsule, 5 mg (NDC 0069-4380-71)Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023
Progesterone Vaginal Gel Urology
- Crinone, Vaginal Gel, 4% (NDC 0023-6150-04)Discontinuation of the manufacture of the drug
Ramelteon Tablet Psychiatry
- Rozerem, Tablet, 8 mg (NDC 64764-805-10)Product is expected to be available through February 2027.
- Rozerem, Tablet, 8 mg (NDC 64764-805-30)Product is expected to be available through June 2027.
Riboflavin 5-phosphate Ophthalmic Solution Ophthalmology
- Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03)Discontinuing manufacture of the product as of July 2026.
Ritonavir Oral Powder Antiviral
- Norvir, Oral Powder, 100 mg (NDC 0074-3399-30)Discontinuation of the manufacture of the drug
Ritonavir Tablet Antiviral
- Norvir, Tablet, 100 mg (NDC 0074-2340-30)Discontinuation of the manufacture of the drug
Rivaroxaban For Suspension Hematology
- Xarelto, For Suspension, 155 mg (NDC 50458-575-01)Business Decision
Rivastigmine Film, Extended Release Neurology
- Rivastigmine, Film, Extended Release, 4.6 mg/24 h (NDC 0378-9070-93)Discontinuation of the manufacture of the drug.
Semaglutide Tablet Endocrinology/Metabolism
- Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
- Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
- Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
Sodium Chloride 0.9% Injection Gastroenterology, Other, Renal
- Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67)Discontinuation of the manufacture of the drug
- Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02)Discontinuation of the manufacture of the drug
- Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66)Discontinuation of the manufacture of the drug
Sodium Oxybate Solution Psychiatry
- Sodium Oxybate, Solution, .5 g/1 mL (NDC 69238-2391-1)Discontinuation of the manufacture of the drug
Somatropin Injection Endocrinology/Metabolism
- Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)Discontinuation of the manufacture of the drug
Spironolactone Tablet Cardiovascular
- Aldactone, Tablet, 100 mg (NDC 0025-1031-31)Discontinuation of the manufacture of the drug.
- Aldactone, Tablet, 25 mg (NDC 0025-1001-31)Discontinuation of the manufacture of the drug.
Succinylcholine Chloride Injection Anesthesia
- Succinylcholine Chloride, Injection, 20 mg/1 mL (NDC 63323-943-10)Discontinuation of the manufacture of the drug
Sulconazole Nitrate Solution Dermatology
- Exelderm, Solution, 1.0% 30 mL (NDC 69489-721-30)Discontinuation of the manufacture of the drug
- Exelderm, Solution, 1.0% 5 mL (NDC 69489-721-05)Discontinuation of the manufacture of the drug
- Sulconazole Nitrate, Solution, 30 mL (NDC 72143-321-30)Discontinuation of the manufacture of the drug. Manufactured for JG Pharma
Tadalafil Tablet Cardiovascular
- Adcirca, Tablet, 20 mg (NDC 66302-467-60)Discontinuation of the manufacture of the drug
Tazemetostat Hydrobromide Tablet Oncology
- Tazverik, Tablet, 200 mg (NDC 72607-100-00)Discontinuation of the manufacture of the drug product
Tiagabine Hydrochloride Tablet Neurology
- Tiagabine Hydrochloride, Tablet, 12mg 30 count (NDC 0093-8072-56)Discontinuation of the manufacture of the drug
- Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56)Discontinuation of the manufacture of the drug
- Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56)Discontinuation of the manufacture of the drug
- Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56)Discontinuation of the manufacture of the drug
Tobramycin Sulfate Injection Anti-Infective
- Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01)Discontinuation of the manufacture of the drug
Travoprost Ophthalmic Solution Ophthalmology
- Travoprost, Ophthalmic Solution, 0.004%, 2.5 mL (NDC 0378-9651-32)Discontinuation of the manufacture of the drug
- Travoprost, Ophthalmic Solution, 0.004%, 5 mL (NDC 0378-9651-50)Discontinuation of the manufacture of the drug
Ursodiol Capsule Other
- Ursodiol, Capsule, 300 mg (NDC 64380-844-06)Discontinuation of the manufacture of the drug
Valrubicin Solution Oncology
- Valstar Preservative Free, Solution, 40 mg/1 mL (NDC 67979-001-01)Discontinuation of the manufacture of the drug
Valsartan Tablet Cardiovascular
- Valsartan, Tablet, 160 mg (NDC 0378-5814-77)A business decision was made to discontinue manufacture of the drug.
- Valsartan, Tablet, 320 mg (NDC 0378-5815-77)A business decision was made to discontinue manufacture of the drug.
- Valsartan, Tablet, 40 mg (NDC 0378-5807-93)A business decision was made to discontinue manufacture of the drug.
- Valsartan, Tablet, 80 mg (NDC 0378-5813-77)A business decision was made to discontinue manufacture of the drug.
Vancomycin Hydrochloride Injection Anti-Infective
- Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01)Discontinuation of the manufacture of the drug
Verapamil Hydrochloride Injection Cardiovascular
- Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05)Discontinuation of the manufacture of the drug
Vigabatrin Tablet Neurology
- Vigabatrin, Tablet, 500 mg (NDC 0054-0652-25)The decision to discontinue this drug product was due to a business decision and not due to any reasons of safety or effectiveness.
Recently resolved
Can't get your medicine?
No comments yet. Questions, tips, what worked for you - start the conversation.